Placebo

Researchers said it remains unclear whether low procalcitonin levels can be used to safely withhold antibiotics in patients with lower respiratory tract infection.

In double-blind, placebo-controlled cannabinoid trials, placebo was significantly associated with pain reduction. Still, the trials received positive media attention, which researchers said could shape the results of future cannabinoid trials.

The placebo effect may play a role in the results of randomized controlled trials investigating medications for vasomotor symptoms, according to a meta-analysis published in Menopause.

ORLANDO — In this video from ASN Kidney Week, Jonathan Barratt, MBChB, PhD, discusses Calliditas Therapeutics’ Tarpeyo treatment, previously known as Nefecon, for patients with IgA nephropathy.

CHARLOTTE, N.C. — In a Healio video exclusive, David T. Rubin, MD, FACG, reported guselkumab induced greater improvement across key outcomes compared with placebo among patients with moderate to severe ulcerative colitis.

TAMPA, Fla. — According to presented results, NSAIDs and gabapentinoids do not substantially increase nonunion rates; however, these may not improve pain control or decrease opioid utilization in orthopedic trauma patients.

Administration of minocycline as an add-on to therapy as usual for those with treatment-resistant depression was nonsuperior to placebo after 6 weeks, according to a study published in JAMA Network Open.

Litifilimab is superior to placebo in improving CLASI-A scores among patients with cutaneous lupus erythematosus over 16 weeks, according to data published in the New England Journal of Medicine.

Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in patients with rheumatoid arthritis who were receiving methotrexate as a maintenance therapy, according to data.

Calliditas Therapeutics AB announced the European Commission gave conditional marketing authorization for Kinpeygo.